Caelyx: phase II studies in ovarian cancer.

  title={Caelyx: phase II studies in ovarian cancer.},
  author={Stephen R. D. Johnston and Martin Eric Gore},
  journal={European journal of cancer},
  volume={37 Suppl 9},
While there have been significant advances in first-line chemotherapy for advanced ovarian cancer, most patients still relapse with drug-resistant disease. For patients refractory to the two most active agents (platinum and paclitaxel), there are few salvage regimens that possess significant clinical activity together with minimal treatment-related toxicities. Caelyx is a new treatment for advanced ovarian cancer, which delivers doxorubicin encapsulated in long-circulating Stealth liposomes… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 15 extracted citations

Role of nanocarrier systems in cancer nanotherapy.

Journal of liposome research • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…